Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIRG: Keytruda in Newly Diagnosed Glioblastoma Multiforme
NCT05235737Phase 4Recruiting
- Sponsor
- Medical University of Silesia
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pembrolizumab in glioblastoma multiforme (GBM), sponsored by Medical University of Silesia. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05235737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235737.